Status:
RECRUITING
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Lupus Nephritis (LN)
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This study is researching a particular group of experimental drugs administered for a short period in the treatment of patients with Lupus Nephritis (LN). The main aim of the current study is to see ...
Eligibility Criteria
Inclusion
- Key General
- Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
- Participant must have refractory or relapsed disease, as described in the protocol
- Key General
Exclusion
- History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization
- Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
- Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening
- NOTE: Other protocol defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
December 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 23 2028
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06975787
Start Date
December 22 2025
End Date
July 23 2028
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080